Novavax's COVID-19 Vaccine Granted Expanded Conditional Authorization In U.K. For Adolescents

Novavax Inc. (NVAX) said Friday that the Medicines and Healthcare products Regulatory Agency or MHRA in the United Kingdom (UK) has granted expanded conditional marketing authorization or CMA for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 in adolescents aged 12 through 17.

The company noted that Nuvaxovid will be the first protein-based vaccine available for adolescents aged 12 through 17 in the United Kingdom.

The next step for the vaccine is a policy recommendation for use from the UK Joint Committee on Vaccination and Immunisation or JCVI. Doses of Nuvaxovid will be made available for use in adolescents based on the JCVI's recommendation.

The MHRA previously granted CMA for Nuvaxovid in adults aged 18 and older in February 2022. The vaccine is given as a primary vaccination in two doses administered 21 days apart. Novavax filed for expanded CMA for use as a booster in adults aged 18 and over in June 2022.

In the 12 through 17 year-old population, the Novavax COVID-19 vaccine has been granted authorization in the U.S., India, the European Union, Australia, Japan, Thailand, and New Zealand, and is actively under review in other markets.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT